Posts

Novo Nordisk Faces Double Departures: GLP-1 Expert Retires as Obesity Leader Joins Boehringer Ingelheim

on
Search results do not contain specific information on recent news about 'Novo's double departures' involving a GLP-1 luminary retiring and an obesity leader moving to Boehringer Ingelheim. Results focus instead on GLP-1 drug studies, including cardiovascular risks from discontinuation 1 , switching medications for better adherence 3 , clinical trials 2 , and drug shortages 4 . No direct mentions of personnel changes at Novo Nordisk or moves to Boehringer Ingelheim in the provided sources. Sources: 1. https://medicine.washu.edu/news/stopping-glp-1-drugs-can-quickly-erase-cardiovascular-benefits/ 2. https://cdn.clinicaltrials.gov/large-docs/77/NCT04667377/Prot_000.pdf 3. https://www.utsouthwestern.edu/newsroom/articles/year-2026/march-glp-1-medication-weight-management.html 4. https://pmc.ncbi.nlm.nih.gov/articles/PMC10338283/

FDA Rejects Replimune's RP1 Melanoma Treatment for Second Time, Citing Unresolved Trial Issues

on

Seaport Therapeutics and Hemab Therapeutics File for IPOs

on

Miltenyi Bio's CAR-T Clears Triple Autoimmune Burden in Single Patient

on

AilsynBio and Dong-E-E-Jiao Sign Project Cooperation Agreement Empowering Traditional Medicine with AI

on

Post-Hoc Live: Biopharma M&A Surge Signals Industry Revival

on

China's Oricell Raises $110M for CAR-T Cancer Therapy Development Ahead of IPO

on

ArkBio Completes Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate AK0406

on

Avalyn Pharma Files for Nasdaq IPO to Advance Inhaled Pulmonary Fibrosis Treatments

on

GoodRx Expands Access to Eli Lilly's New Oral GLP-1 Foundayo and Zepbound KwikPen with Self-Pay Pricing at Over 70,000 Pharmacies

on

Sibel Health Receives FDA Clearance for ANNE Maternal Wireless Maternal-Fetal Monitoring Platform

on

Garda Therapeutics Acquires Assertio and Rolvedon in $125.1M Deal

on

AbbVie Sues Over 'Outdated' 340B Patient Definition in New Lawsuit

on